Rt023

Preclinical

SShanghai Ruotuo Biosciences Co., Ltd.

Rt023 is one of 4 therapeutic programs targeting Advanced Malignant Solid Tumours. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Malignant Solid TumoursNot yet recruiting

Advanced Malignant Solid TumoursPreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Advanced Malignant Solid Tumours

#DrugCompanyPhaseTrials

SCTB41

SSinocelltech Ltd.

Phase 2

1 2

SCTB14

SSinocelltech Ltd.

Phase 2

1 3

JS212

SShanghai Junshi Bioscience Co., Ltd.

Preclinical

1 4

Rt023

SShanghai Ruotuo Biosciences Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalNot yet recruiting

Advanced Malignant Solid Tumours

NCT07797426

Clinical

Trials by Indication[1]

Advanced Malignant Solid Tumours1 trial

A Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RT023 in Patients With Advanced Solid Tumors

Not yet recruiting·SShanghai Ruotuo Biosciences Co., Ltd.·Preclinical·NCT07797426·318 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rt023. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rt023. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Ruotuo Biosciences Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShanghai Ruotuo Biosciences Co., Ltd.

Rt023

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Advanced Malignant Solid Tumours1 trial

References

Drug Info

Quick Facts

Related News